论文部分内容阅读
目的观察普拉克索联合美多巴治疗晚期帕金森病(PD)的临床疗效。方法选取2013年5月—2014年5月黄河三门峡医院收治的晚期PD患者86例,随机分为试验组和对照组各43例,分别给予普拉克索联合美多巴和吡贝地尔联合美多巴治疗,比较两组患者临床疗效,治疗前和治疗后4周、8周、12周帕金森评分量表Ⅲ(UPDRSⅢ)评分和汉密尔顿抑郁量表(HAMD)评分,记录治疗期间不良反应情况。结果试验组患者临床疗效优于对照组(P<0.05)。两组患者治疗前、治疗后4周UPDRSⅢ评分、HAMD评分比较,差异均无统计学意义(P>0.05);试验组患者治疗后8周、12周UPDRSⅢ评分、HAMD评分均低于对照组(P<0.05);两组患者头晕、恶心呕吐、嗜睡、便秘、开关现象、精神症状发生率比较,差异无统计学意义(P>0.05)。结论普拉克索联合美多巴联合治疗晚期PD临床疗效确切,可有效改善患者运动障碍症状和抑郁症状,且不良反应轻,可作为治疗晚期PD的优选方案。
Objective To observe the clinical efficacy of pramipexole combined with metopar in the treatment of advanced Parkinson’s disease (PD). Methods Eighty-six patients with advanced PD who were admitted to Sanmenxia Hospital of the Yellow River from May 2013 to May 2014 were randomly divided into experimental group and control group, with 43 cases in each. Patients were given pramipexole combined with meclopa and piribedil To compare the clinical curative effect between the two groups, before and after treatment, 4 weeks, 8 weeks and 12 weeks after treatment, the Parkinson’s Rating Scale Ⅲ (UPDRS Ⅲ) score and the Hamilton Depression Rating Scale (HAMD) score were recorded. The adverse reactions during the treatment . Results The clinical efficacy of the experimental group was better than that of the control group (P <0.05). There was no significant difference in UPDRSⅢscore and HAMD score between the two groups before treatment and 4 weeks after treatment (P> 0.05). The UPDRSⅢand HAMD scores of the two groups were lower than those of the control group P <0.05). There was no significant difference in the incidence of dizziness, nausea and vomiting, drowsiness, constipation, switching and mental symptoms between the two groups (P> 0.05). Conclusion The combination of pramipexole and metoparb in the treatment of advanced PD has definite clinical curative effect, which can effectively improve the symptoms and depressive symptoms of patients with dyskinesia and has mild side effects. It can be used as the optimal treatment for advanced PD.